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Introduction: As noted in National Council on Radiation Protection and Measurements 
(NCRP) Report 151, the medical physicist or other qualified expert has the responsibility to keep 
abreast of any new technology or treatment method that could potentially impact structural 
shielding design. Volumetric arc therapy (VMAT) became prevalent after the publication of 
Report 151 and thus was not explicitly addressed in Report 151. If the shielding-related 
characteristics of VMAT differ enough from the expectations of Report 151, especially in the 
circumstance of a vault utilized exclusively for VMAT, a shielding design based on Report 151 
could potentially be inadequate. The goal of this work was (1) to assess the characteristics of 
VMAT deliveries that potentially impact shielding design, and (2) to determine if Report 151, as 
published and incorporating only minimal conservative design choices, will result in a safe 
shielding design for a dedicated VMAT treatment vault. Three shielding parameters were 
characterized: workload, VMAT modulation factor, and use factors. 
Materials and Methods: A secondary verification system, MobiusLog (Mobius Medical 
Systems, LP, Houston, TX) was used to obtain real-time mechanical tracking of VMAT deliveries 
on five linear accelerators at three facilities over a 4-month period. After anonymization, these log 
files were analyzed by individual accelerators and by type of treatment site (e.g., chest, head & 
neck, prostate), as well as collectively. The fractionation scheme for each patient was used to 
compute weekly workloads and VMAT modulation factors. Use factors were determined from 
reported gantry positions during treatment, for 90° (conventional), 45° (IMRT), 30°, and 15° 
angular binning intervals, and compared to Report 151. Using the VMAT-specific parameters, 
shielding was designed for a sample vault; these barriers were compared to barriers designed with 
parameters from Report 151.  
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Results: Workloads derived from the log files agreed with independent clinic records, 
indicating the log files contained complete delivery information. Composited over all accelerators 
and treatment sites, the use factors were essentially uniformly distributed around the full circle; 
deviations from uniform were most noticeable at the smaller binning intervals and for the 0° (beam 
directed at floor) and 180° (beam directed at ceiling) intervals. The use factors per treatment site 
were also relatively uniformly distributed, except for lung and chest sites. The sample vault design 
showed that the Report 151 use factors occasionally underestimated barrier requirements 
compared to log file-based VMAT use factors or the assumption of uniform gantry rotation. The 
inclusion of reasonable conservative margins on calculations may allow Report 151-based barriers 
to be adequately safe. A tapered ceiling barrier that is designed using Report 151’s 45° (IMRT) 
interval use factors will not yield a safe shielding design. The VMAT-specific data should not 
significantly impact the design calculations for secondary barriers or doors, primarily because 
these barriers are independent of use factor. 
Conclusion: The VMAT-specific use factors reported in this work, as well as the assumption 
of uniformly-distributed use factors, consistently led to primary barrier thicknesses that were at 
least as safe as those calculated from published Report 151 use factors. Shielding calculations 
based on Report 151 can produce adequate primary barriers for a dedicated VMAT vault only if 
the qualified expert incorporates sufficient conservative overestimates, i.e., enough to compensate 
for the larger VMAT use factors, in some barriers. A tapered ceiling barrier in a dedicated VMAT 
vault should be designed using either VMAT-specific use factors or assumed uniformly-distributed 
use factors, not the published 45° (IMRT) interval use factors of Report 151. The assumption of 
uniformly distributed use factors is reasonable for designing a general-purpose VMAT vault, but 
vii 
treatment site-specific use factors should be used to design a vault that will be used heavily for 
only one (or a few) treatment sites, such as chest or lung. 
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Chapter 1. Introduction 
This chapter presents the motivation and background information pertinent to this research 
work. The motivation describes the importance of assessing the potential impact of newly 
developed radiotherapy treatment methods on current structural shielding design methods. The 
background reviews the current state of practice for structural shielding design as well as the 
radiotherapy treatment approach of volumetric arc therapy (VMAT). The chapter concludes with 
the hypothesis and specific aims of this work. 
1.1. Motivation 
The goal of radiation protection is to minimize the likelihood of radiation-induced harm to 
radiation workers and the general public (NCRP, 1993). Medical physicists and similar qualified 
experts use three principles to reduce radiation exposure: time, distance, and shielding. In a 
megavoltage clinical radiotherapy facility, the time spent near and the distance from a radiation 
source are often dictated by facility operations; therefore, physical shielding is the primary tool to 
minimize the exposure of radiation workers and the general public alike. The National Council on 
Radiation Protection and Measurements (NCRP) is the primary entity in the U.S. that recommends 
procedures for the design of structural shielding. The NCRP brings together representatives of 
government, industry, academia and other stakeholders to offer consensus guidelines and summary 
information related to radiation protection practices (NCRP, 2019). 
In 2005, the NCRP delineated the most recent recommendations for the design of structural 
shielding for megavoltage x-ray and gamma-ray radiotherapy facilities in Report 151 (NCRP, 
2005). These guidelines were based on the clinical radiation delivery modalities that were common 
at the time of publication. The constantly evolving nature of radiation delivery methods makes it 
the responsibility of the medical physicist or other qualified expert to keep abreast of any new 
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technology that could potentially impact structural shielding design (NCRP, 2005). One recent 
development not included in NCRP Report 151 is volumetric arc therapy (VMAT). This modality 
has quickly become the predominant treatment delivery for tumor sites like prostate, head and 
neck, and breast. (Teoh, Clark, Wood, Whitaker, & Nisbet, 2011). VMAT has seen rapid and 
widespread adoption because this technology can be implemented on a conventional clinical linear 
accelerator that is already equipped with multileaf collimators for intensity-modulated radiation 
therapy (IMRT). No specialized radiation source or geometry is required, unlike tomotherapy 
(Robinson, Scrimger, Field, & Fallone, 2000), robotic arm systems (Rodgers, 2005), or gamma 
knife (McDermott, 2007). With fast and accurate delivery of arcs (Teoh et al., 2011), and easy 
implementation, most facilities have upgraded their accelerators to also deliver VMAT treatments.  
Few attempts have been made to analyze the impact that arc therapy has on the various 
parameters for the design of structural shielding (Teoh et al., 2011). No reports have been found 
in the literature of IMRT treatment vaults being inadequate for VMAT. Two possible reasons are 
(1) conservative margins added onto designs have fortuitously been sufficient for VMAT, and (2) 
any potentially inadequate vaults were remediated but the effort was not written up for publication. 
In any case, Report 151 does not explicitly account for VMAT deliveries and thus potentially could 
result in an inadequate vault design especially in the circumstance of a vault utilized exclusively 
for VMAT. Therefore, this thesis work will characterize VMAT deliveries relative to shielding 
design parameters and analyze their potential impact on Report 151-based shielding design. This 
work will recommend modified procedures and provide supplemental data that may be used by 
other qualified experts to design new treatment vaults or to evaluate existing vaults for substantial 
use of VMAT.  
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1.2. Background  
1.2.1. History of radiation protection and NCRP  
The discovery of x-rays and radioactive processes in the late 19th century revolutionized the 
medical imaging field. Not long after its discovery, radiation proved to be beneficial as a curative 
method, and soon after started to be implemented in all sorts of therapeutic modalities (Inkret, 
Meinhold, & Taschner, 1995). While radiation was found to be beneficial, adverse effects were 
soon observed (Grossman, 1982); this served as the early motivation for physicists to create 
radiation protection societies in the U.S. and elsewhere (Inkret et al., 1995). These societies sought 
to develop and promulgate guidelines for the safe use of radiation. The societies in the U.S. 
eventually developed into the National Council for Radiation Protection and Measurements 
(NCRP 151, 2005). In 1993 the NCRP published Report 116 which proposed the current limit for 
radiation exposure in the United States; for radiation workers, the annual exposure limit is 50 
mSv/year while the general public is limited to 1 mSv/year (NCRP, 1993). In 2005, the NCRP 
published Report 151, the current guidelines for structural radiation shielding design of 
radiotherapy facilities (NCRP, 2005). 
1.2.2. NCRP Report 151: Structural Shielding Design and Evaluation for Megavoltage X- and 
Gamma-ray Radiotherapy Facilities 
Report 151 presents the current recommendations related to the design and installation of 
structural shielding at megavoltage radiotherapy facilities (NCRP, 2005). This publication 
consolidated, revised, and extended the shielding design recommendations in Report 49 (NCRP, 
1976), Report 51 (NCRP, 1977), and Report 79 (NCRP, 1986). Report 151 included IMRT 
treatment methods which had become widespread in the preceding decade. Report 151 presents 
methods and supplemental data to calculate required barrier thicknesses to keep potential radiation 
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exposures of workers and the public below regulatory limits. The following paragraphs review the 
Report 151 formalism. 
The purpose of a radiation barrier is to attenuate any radiation incident on the barrier, to bring 
the dose equivalent (H) beyond the barrier to or below acceptable limits. Called the design goal 
(P), these limits are based on regulatory limits (10 C.F.R. § 20, 1991) and ALARA practice; NCRP 
sets design goals of 0.1 mSv/week for radiation workers and 0.02 mSv/week for the general public. 
Barrier thickness per Report 151 depends on the type and magnitude of radiation that is incident 
on the barrier, as well as characteristics of the area that is being protected. Walls, ceiling, floor, 
and door in a linac vault all serve as shielding barriers. 
A barrier that sees direct incidence of the therapeutic field from the radiation source is 
designated a primary barrier. The shielding parameters necessary to calculate primary barrier 
thickness are:  
- Workload (W) which is the weekly average photon absorbed dose delivered to 
isocenter. (See Report 151 for additional stipulations)  
- Use factor (U) which is the fraction of the workload that is delivered towards a given 
primary barrier 
- Distance (d) which is the distance from the source to the point of protection beyond the 
barrier. Radiation intensity decreases with distance based on the inverse square law; 
Report 151 stipulates that the closest a protected person’s critical organs can get to the 
barrier for a significant amount of time is 0.3 m 
- Occupancy factor (T) which is the fraction of time that the protected person is present 
beyond the barrier 
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With reference to the design goal, these shielding parameters yield the barrier’s transmission factor 
(B). The transmission factor is the ratio of the design goal (dose equivalent allowed) to the radiation 
reaching the point of protection with no barrier present. Therefore, the transmission factor for a 




and represents the fraction to which the barrier shielding must attenuate the primary beam.  
A secondary barrier is the one that does not see direct incidence of the radiation beam but can 
receive leakage radiation from the source, scattered radiation from the patient and treatment 
apparatus (and from walls in some circumstances), and photoneutrons and neutron-capture gamma 
rays. Photoneutrons and neutron-capture gamma rays only become a concern for shielding design 
when the linac’s operating potential is above 10 MV, and thus are not a concern for VMAT (NCRP, 
2005). Arising from primary radiation, scatter and leakage magnitudes at the point of protection 
are derived from workload (Kermani, Leclerc, Martel, & Fareh, 2001; NCRP, 2005). Because 
scatter and leakage are produced whenever the source is energized and are emitted in all directions 
regardless of the direction in which the gantry points, the use factor for secondary radiation is 
always 1. A properly designed primary barrier is sufficient to also shield any secondary radiation 
incident upon it (NCRP, 2005), because secondary radiation is potentially several orders of 
magnitude lower in intensity than the primary beam workload. 
To calculate the dose equivalent due to scatter at the point of protection beyond a secondary 
barrier, several shielding parameters are required in addition to workload. These are:  
- Scatter distance (dsca) which is the distance from the radiation source to the scattering 
site 
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- Secondary distance (dsec) which is the distance from the scattering site to the point of 
protection located 0.3 m past the barrier 
- Scatter fraction (a) which is the fraction of the workload that scatters from the patient 
in the direction of the barrier; scatter fraction is tabulated in Report 151 for a 20x20 
cm2 treatment field 
- Field area (F) which is the area of the treatment field, measured at isocenter (usually 
1 m from the source) 
The transmission factor required from the barrier to reduce scatter at the point of protection to the 




Leakage radiation is due to penetration of stray radiation through the shielding around the linac 
source. Manufacturers are required to provide head shielding that attenuates no less than 99.9% of 
this stray radiation, i.e., only 0.1% is incident on structural barriers (NCRP, 1989); the head 
shielding thus has a transmission factor of 10-3.  
The amount of leakage is proportional to the total radiation produced by the accelerator to 
achieve the desired workload at isocenter; some treatment techniques may require substantially 
more radiation production by the accelerator compared to the workload measured at isocenter. For 
instance, treatment techniques like IMRT and VMAT stitch together many small collimated fields, 
blocking much of the primary beam at any moment but still contributing to leakage. Therefore, for 
modulated radiation therapy, the leakage workload needs to be accounted for. In Report 151, 
Leakage factor (C) is defined as the ratio of monitor units (MU) needed to deliver 1 cGy to 
isocenter with small blocked fields to the MU needed to deliver 1 cGy to isocenter with a large 
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open field. For IMRT, the higher monitor units produced to deliver a prescribed dose per patient 








The dose equivalent at the point of protection due to leakage thus depends, in addition to 
workload, the mandatory head transmission of 10-3, and leakage factor, on:  
- Leakage distance (dL) which is the distance from the source to the point of protection 
located 0.3 m beyond the secondary barrier. This distance can be measured from 
isocenter in some circumstances (NCRP, 2005). 







for modulated fields. For an unmodulated (open) field, C=1 and the leakage workload is the same 
as the primary workload.   
Once the transmission factors are computed, the thickness of both primary and secondary 
barriers is determined based from the operating energy of the accelerator and the type of material 
that will be used in the barrier. For convenience, the attenuating properties of materials are 
characterized by the tenth value layer (TVL), rather than the more familiar attenuation coefficient 
for exponential attenuation. One TVL of material attenuates a radiation beam to one-tenth of its 
initial value. The number of TVLs (n) needed to attenuate the beam to the design goal is derived 
from the transmission factor as:   
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 𝑛 =  −log (𝐵) (Eq. 6) 
Report 151 tabulates TVLs for commonly used materials such as concrete and lead, for a range of 
common operating voltages.  
The bremsstrahlung x-rays produced by a radiotherapy linear accelerator are polychromatic. 
Due to spectral changes in this radiation as it passes through the barrier, the effective attenuation 
coefficient is not constant. For shielding purposes, more material is required to achieve the first 
10x reduction in beam intensity (TVL1), compared to subsequent reductions (TVLe). The thickness 
of a barrier that requires n TVLs therefore is defined by:  
 𝑡𝑏𝑎𝑟𝑟𝑖𝑒𝑟 = 𝑇𝑉𝐿1 + (𝑛 − 1)𝑇𝑉𝐿𝑒 (Eq. 7) 
Prior to Report 151, several research studies showed that IMRT techniques had a leakage 
workload two to three times greater than a conventional 4-field delivery (Mechalakos, Germain, 
& Burman, 2004). A higher leakage workload directly increases the required thicknesses of all 
secondary barriers. However, particular treatment techniques may affect specific barriers, such as 
by altering the numbers and directions of treatment beams relative to conventional methods. The 
impact of new treatment techniques such as VMAT on shielding design must be assessed, to ensure 
that both existing and new vaults are certain to protect radiation workers and the public.   
1.2.3. Volumetric Arc Therapy  
Modulated field deliveries were a solution to many tumor conformality issues while sparing at 
risk structures near the treated site (Teoh et al., 2011). Intensity modulated radiotherapy (IMRT) 
relies on field modulation through multi leaf collimators (MLCs) in the beam’s path to conform to 
a structure, while sparing close-by organs. IMRT also uses variable dose delivery across beamlets 
to achieve dose conformality to the tumor while also implementing different beam positions 
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around the patient. Each beam can deliver a different modulated field at each step; hence this 
delivery method is called step-and-shoot delivery (Yu & Tang, 2011).  
A standard IMRT plan often requires multiple fixed angle radiation beams, which increases 
treatment delivery time.  Better conformality requires more beams and more complex treatment 
plans, which makes IMRT not only time consuming to deliver the plan itself, but also time 
consuming to plan. To improve the complexity and long treatment times, in 1995 Yu proposed the 
idea of intensity modulated arc therapy (IMAT) (Yu, 1995). Arc therapy is based on the concept 
of delivering radiation by rotating the radiation source at a full 360º beam angle. When it was first 
proposed, IMAT relied on the use of multiple arcs superimposed to achieve conformality while 
still modulating the field via MLCs (Yu, 1995). 
Arc therapy continuously delivers radiation while adapting the beam’s field shape to the 
tumor’s shape (Khan, 2014). However, when IMAT was first introduced the available technology 
had limitations, and several different approaches were used to achieve the superposition of arcs 
with little success of becoming commercialized (Yu & Tang, 2011). In 2008, volumetric arc 
therapy (VMAT) was introduced as a single-arc IMAT technique that could achieve dose rate 
variation with different segment weights throughout a single-arc rotation (Otto, 2008). VMAT 
simultaneously varies three parameters during the beam deliver: gantry speed, aperture shape (via 
MLCs), and dose rate; VMAT soon became rapidly commercialized (Otto, 2008). Nowadays, the 
entire treatment volume can be treated with one or two arcs, although more complex cases may 
use more arcs (Teoh et al., 2011).  
1.2.4. Impact of VMAT on shielding design 
Occurring after the publication of Report 151, volumetric arc therapy (VMAT) has now been 
widely implemented in radiotherapy facilities and has also become the predominant treatment 
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delivery method for tumor sites like prostate, head and neck, and breast (Teoh et al., 2011). One 
of the reasons why VMAT is easily implemented is that this technology can be adapted to a 
conventional linear accelerator, just like IMRT. With the increase and versatility in the 
implementation of this technology, most facilities have upgraded their linacs to deliver VMAT 
treatments. Early studies of VMAT suggested that this delivery has an increased leakage workload 
(Teoh et al., 2011) when compared to a conventional open-field delivery technique, similar to 
IMRT. Simultaneously, with VMAT reducing the overall treatment time, primary weekly 
workloads have not significantly increased. The overall treatment time that is saved for each 
patient using arc delivery, is usually offset by treating more patients daily (Saleh et al., 2017). 
Although no reports have been found in the literature about insufficiency of existing treatment 
vaults for VMAT delivery, few attempts have been made to analyze the impact that arc therapy 
has on the various parameters for the design of structural shielding (Teoh et al., 2011).  
Relevant recent studies included retrospective analysis of VMAT’s primary workload in 
different centers. Reis, Alves, & Fairbank (2019) suggested that a “VMAT Factor” or “modulation 
factor” should be introduced to account for radiation incident on secondary barriers. This proposed 
factor included the effects of increased radiation production, different field collimation, lower 
beam-on time, and variable dose rate. This factor is analogous to the “IMRT factor” of Report 151 
(referred to as C earlier), and their calculation was identical. Their VMAT factor was lower than 
the corresponding IMRT factor would be for the same barrier and same angular direction; however, 
the difference was not established within statistical certainty. This study also recognized that the 
treatment site and fractionation could have a substantial impact on the workload distribution (i.e., 
use factors), but it was not in their scope to quantify this effect (Reis, Alves, & Fairbanks, 2019). 
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In 2010, a retrospective study was carried out at Memorial Sloan Kettering Cancer Center to 
analyze the impact on workload of several treatment modalities over a 10-year timeline. Treatment 
of different anatomical sites yielded significant differences for the use factors in individual 
treatment vaults, mainly because of the type of treatment applied to particular sites; when all 
treatment rooms were aggregated, the differences became insignificant (Saleh et al., 2017). Figure 
1.1 presents their results on the spatial distribution of the workload, i.e., use factor, shown as a 
rose plot for each type of treatment. These plots clearly indicate that the spatial distributions of use 
factors are quite different between VMAT and IMRT. This study indicated that the main reason 
for this difference is due to each delivery technique catering to specific treatment sites, but no 
proof of this claim was presented. 
 
Figure 1.1. Use factors represented as rose plots comparing IMRT and VMAT, aggregated 
for all treatment vaults over a period of one year. Source: Saleh et al., 2017. 
1.3. Hypothesis and specific aims 
The goal of this project was to assess the impact of VMAT treatment delivery on the design of 
structural shielding using the methods in Report 151. One aspect was to determine if a vault 
designed exclusively for VMAT but using only the data available in Report 151, with essentially 
no additional conservative margin, results in a vault design that would meet design goals. A second 
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aspect was to identify VMAT-specific issues and to collate VMAT-specific data that could be 
incorporated into Report 151, ensuring that a vault exclusively designed for VMAT treatments, 
with minimal conservative margin, would be certain to meet design goals. In other words, is Report 
151 as written conservatively safe for VMAT? If not, what additional information or modified 
methods would render it so? 
1.3.1. Hypothesis 
The hypothesis for this work is that Report 151, as published, results in a safe shielding design 
for a dedicated VMAT treatment vault. In other words, the shielding for a linac vault that delivers 
only VMAT, designed using the methods and supporting data available in Report 151, and 
incorporating minimal conservative overestimates of parameters, will not exceed design goals for 
any barrier. The choice of this hypothesis was based on the lack of reports regarding inadequate 
vaults in the literature. 
1.3.2. Specific Aims 
1. Collect linac log files for VMAT deliveries from five Elekta linacs at Mary Bird Perkins 
Cancer Center over 4 months; then catalog the use factors and other patient metrics 
(workload and modulation) by treatment sites.  
2. For a typical vault design, derived from an existing vault used for VMAT, compare barrier 
calculations based on (a) the use factors determined in Aim 1, (b) the assumption of 
uniformly distributed use factors, and (c) the IMRT use factors from Report 151. The same 
minimal conservative margins will be utilized for all cases.  
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Chapter 2. Data collection methods  
This chapter describes the methods used for collection and analysis of linac operation data for 
VMAT deliveries. Treatment-related metrics were summarized to delineate the “typical weekly 
workload” for this data; qualified experts can utilize these metrics to assess the results and 
recommendations of this work relative to their facilities.  
2.1. Accelerators and facilities 
This VMAT data was collected from five linear accelerators at three facilities operated by the 
Mary Bird Perkins Cancer Center (MBPCC) in Baton Rouge, in Covington, and in Gonzalez. The 
five accelerators were all manufactured by Elekta. One linac in Baton Rouge (BR1) was an Agility 
model while the other (BR2) was a Versa HD model. Both linacs in Covington (CV1 and CV2) 
and the linac in Gonzalez (GON) were Agility models. The Elekta Versa HD model is an upgrade 
to the Agility, providing high dose rates for SBRT and SRS treatments; these models have no 
significant differences in terms of shielding design, however. All linacs are used daily for a mix 
of VMAT and other types of treatment deliveries. 
2.2. Collection of linac operation data 
2.2.1. Linac log files 
During any radiotherapy delivery, the treatment control system of the linac records the 
complete machine state at a sampling rate of 4 Hz. After each delivery, this log file is temporarily 
available for retrieval from the linac (Grenier, 2013). MobiusLog (Mobius Medical System, LP, 
Houston, TX) is the software package used at MBPCC to retrieve and archive the log file. 
MobiusLog can record 200-300 control points per delivery; each control point records mechanical 
parameters such as timestamp, gantry position, monitor units delivered, collimator position, and 
leaf position data. Each log file is uniquely named so that the data can be associated to the patient’s 
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treatment records. The log file also records the patient ID number, patient name, and the delivery 
date and time.  
Log files were collected by MobiusLog for all treatment deliveries on the five linacs over a 4 
month period. MobiusLog writes the log file data into two files, one containing the treatment 
information (with a ‘.elog’ extension) and the other (with a ‘.ebin’ extension) containing the real 
time linac mechanical state recorded at the 4 Hz sampling rate. The ‘.elog’ file is written in human-
readable format as shown in Figure 2.1, while the ‘.ebin’ file has a human-readable header 
followed by binary data which must be decoded, as shown in Figure 2.2. All files were anonymized 
by removing or overwriting patient specific data, and by renaming the files with the date and 
timestamp only.   
 
Figure 2.1. Screen capture comparing the contents of an ‘.elog’ file generated by 
MobiusLog. The ‘.elog’ file only contains a header with information of the 
treatment set up. i.e. beam name, technique, and delivered Mus The “Columns” row 
of the header lists the categories of data contained in the ‘.ebin’ file. 
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Figure 2.2. Screen capture comparing the contents of an ‘.ebin’ file generated by 
MobiusLog. This ‘.ebin’ file contains a header with treatment information followed 
by binary data that needs further decoding and contains the gantry mechanical state 
at control points and the “Columns” row of the header lists the categories of data 
contained in the ‘.ebin’ file. 
2.2.2. Data parsing from log files 
Each ‘.ebin’ file was parsed using an in-house Python Spyder script. The binary portion of an 
‘.ebin’ file contained 1400 bytes of information per control point. The first 120 bytes recorded 17 
variables describing the radiation beam’s position and state, with the data stored in an order 
indicated in the file header. The pertinent beam information for this project included the control 
point’s timestamp (in milliseconds since the start time of the arc’s delivery), position of the gantry, 
beam state, dose rate, and monitor units delivered. The remaining bytes for each control point 
contained position of the collimator, couch angular position, whether external beam modulators 
were used, and state information about the 80 leaves of the multileaf collimator, which were not 
relevant to this work. The Python script determined the number of control points from the amount 
of binary data stored in the file, and allocated storage for the data of each control point. The binary 
data was then read byte by byte as a big-endian single-precision float type. The parsed data was 
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written into a ‘.csv’ format spreadsheet for subsequent analysis. The timestamp and treatment site 
were used as the ‘.csv’ file’s name. 
The treatment site and delivery method (conventional, IMRT, or VMAT) was determined from 
the headers of the ‘.ebin’ and ‘.elog’ files. The python script contained a set of logical conditions 
that classified the treatment site based on key words, e.g. sites containing the keywords prostate 
or prostatic were classified as pelvis for the treatment site. Eight classifications were chosen for 
treatment sites: abdomen, chest (treatment to the chest wall), head & neck, lung (treatment to a 
tumor within the lung), pelvis (most often, treatment of the prostate), spine, QA, and other. Within 
each type of treatment site, VMAT treatment plans are similar as to how the arcs are planned and 
delivered. These site classifications were chosen in consultation with clinical medical physicists 
at MBPCC (D. Neck and J. Fontenot, private communication), representing the majority of VMAT 
treatments delivered on the five linacs at the three facilities.  
A master spreadsheet was developed to associate the ‘.csv’ file with the original ‘.ebin’ file 
and ‘.elog’ file. The ‘.elog’ file contained information such as the linac name which wasn’t in the 
parsed ‘.ebin’ file, so this global list facilitated crosschecking of information during analysis. The 
global list was also used to tally numbers and types of treatments on each linac per day, numbers 
of beams delivered, and additional information that was used to categorize the delivery data, as 
described in the next section.  
A note on terminology in the following sections, a beam refers to delivery of radiation to the 
patient. For VMAT, one delivered arc is a beam; a VMAT treatment on a single day may comprise 
one, two, or a few arcs. For IMRT, a beam is multiple small (modulated) fields delivered from a 
single gantry position; an IMRT treatment typically delivers a large number of beams. Finally, a 
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conventional treatment delivers one or more static (unmodulated) beams from specific gantry 
positions.  
2.3. Arc delivery metrics 
Log files for treatment deliveries on the 5 linacs were recorded in the months of September, 
October, November, and December of 2020. Overall, MobiusLog recorded 23,895 deliveries 
during this span of 4 months. The number of treatments delivered and to which treatment sites 
varied from day to day; even though patients come in regularly through each week, fluctuations 
occur as new cases start and other treatment courses end. The treatment deliveries were catalogued 
in terms of number of deliveries per treatment site, number of arcs delivered per fraction, 
prescribed dose, and total arcs delivered per patient. In this study, a five-number summary was 
used to describe each metric. The five-number summary included the data series’ minimum, first 
quartile, median, third quartile, and maximum; first and third quartiles are often reported together 
as interquartile range (IQR). The arithmetic mean was also determined; a comparison of mean and 
median can illustrate asymmetry of the data distributions (Massart, Smeyers-Verbeke, Capron, & 
Schlesier, 2005). The summary data was used to analyze workload and modulation. The summary 
data also allows qualified experts to compare the treatment census at their institutions to that 
reported in this work. 
2.3.1. Clinical case metrics 
The clinical case metrics over the 4-month period were combined to define a typical daily 
patient workload for each linac and for all linacs together (all treatment sites combined), as well 
as for each treatment site (all linacs combined). The typical daily workload characterized the total 
number of arcs delivered on an average day. As the first step, the occurrences of the different 
treatment sites across all delivery methods (conventional, IMRT, and VMAT) were determined 
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from the log file data, shown in Table 2.1. Overall, the most frequently treated site was the pelvis, 
with a median daily case count of 61, followed by lung with 55, and then head & neck with 41. 
Table 2.1. Statistics regarding beam deliveries per treatment site for all linacs and all 
treatment methods (conventional, IMRT and VMAT). IQR = interquartile range. 





Beams delivered per day 
Min Mean Median IQR Max 
Abdomen 936 3 12.8 14 [10,15] 20 
Chest 2594 6 34.1 27 [23,35] 48 
H&N 3032 4 35.3 41 [30,35] 65 
Lung 3937 14 51.8 55 [43,63] 82 
Pelvis 4600 24 59.0 61 [51,75] 110 
Spine 1232 2 16.9 14 [10,20] 33 
QA 5006 1 54.4 60 [33,72] 124 
Others 2558 1 32.4 36 [24,42] 58 
*Total number of beams delivered on all 5 linacs over 4-month period 
Analyzing only the VMAT deliveries, the most frequently treated sites were still the pelvis, 
lung, and head & neck (Table 2.2). While VMAT was utilized to some extent for all treatment 
sites, comparing Table 2.2 to Table 2.1 shows that VMAT was the predominant choice of treatment 
method for each of these three sites. VMAT was used almost exclusively for treatment of the pelvis 
(median of 58 VMAT arcs out of 61 beams delivered, or 95%) and head & neck (median of 37 
VMAT arcs out of 41 beams delivered, or 90%).   
2.3.2. Machine metrics 
Table 2.1 and Table 2.2 showed the daily deliveries for each treatment site for all linacs. 
Because shielding is designed individually for each treatment room, Table 2.3 and Table 2.4 
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summarize the delivery data by linac for all treatment sites for all delivery methods and for VMAT 
only, respectively. The data of Table 2.4 is also illustrated in Figure 2.3. These tables illustrate 
differences in utilization of the linacs at the several MBPCC facilities, including the proportions 
of VMAT to other delivery methods.  
Table 2.2. Statistics regarding VMAT arc deliveries per treatment site for all linacs. IQR = 




Arcs delivered per day 
Min Mean Median IQR Max 
Abdomen 468 2 6.5 6 [8,12] 12 
Chest 395 1 5.4  9 [3,12] 13 
Head & 
Neck 
2700 15  32.1  37 [29,42] 51 
Lung 3034 14  40.5  39 [34,49] 64 
Others 963 1  12.5  12 [8,17] 25 
Pelvis 4283 24  55.6  58 [49,70] 89 
QA 387 3  20.4  7 [7,27] 49 
Spine 176 1  3.7  2 [2,4] 7 
*Total number of arcs delivered on all 5 linacs over 4-month period 
The two linacs in Baton Rouge were the most used overall; 62% of treatments (a median of 51 
of 82 beams per day) on BR2 were VMAT deliveries, but only 38% of treatments on BR1 were 
VMAT. Because of the model difference between BR1 and BR2, conventional treatments and 
IMRT are more prevalent on BR1, while BR2 is designed for high dose rate treatment deliveries. 
The three linacs in Covington and Gonzalez were all similar in utilization, with VMAT accounting 
for just under half of all treatments on these linacs. From a qualitative assessment of the master 
spreadsheet, outliers in Figure 2.3 showing heavier and lighter utilization on some linacs likely 
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indicate isolated days of maintenance procedures on a linac when treatments were shifted to 
another linac, as well as heavy QA workloads on some linacs.  
Table 2.3. Statistics regarding beam deliveries per linac for all treatment methods and sites. 





Beams delivered per day 
Min Mean Median IQR Max 
BR1 5161 2 79.4 91.5 [55.0, 103.0] 169 
BR2 6211 32 79.6 82 [65.0, 92.0] 129 
CV1 5525 37 72.7 68.5 [62.0, 79.0] 104 
CV2 4951 33 71.8 71 [60.5, 80.0] 93 
GON 3607 31 63.3 76 [52.0, 76.0] 107 
*Total number of arcs delivered on all 5 linacs over 4-month period 
Table 2.4. Statistics regarding VMAT arc deliveries per linac for all treatment sites. IQR = 




Arcs delivered per day 
Min Mean Median IQR Max 
BR1 2484 2 38.5 35.0 [24,55.5] 87 
BR2 4065 13 52.1 51.0  [43.8,65] 87 
CV1 2286 12 30.1 31.0   [26,35.8] 49 
CV2 2318 16 33.6 34.0  [28,39.5] 52 
GON 1779 16 31.2 32.0  [28,37] 45 
*Total number of arcs delivered on all 5 linacs over 4-month period 
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Figure 2.3. Boxplot illustrating linac usage for VMAT deliveries. The box sides represent 
interquartile range (IQR), which contains 50% of the data points. The line within 
the IQR shows the median, with the cross indicates the mean. The whiskers mark 
the minimum and maximum values of the data range, with outliers (circles) defined 
as points that are more than 1.5 times the IQR from the median value. 
2.3.3. Workload and modulation 
The log files contain information about the beam output at a given control point, measured in 
monitor units (MU), and also the cumulative MU delivered. The beam output is measured by the 
dose monitoring system in the treatment head (Khan, 2014). MU directly measures radiation 
production by the linac. Beam modulation causes the MU to be larger than the workload, i.e., dose 
delivered to isocenter; modulation blocks parts of the produced radiation from reaching the patient. 
Workload can be derived from prescribed dose per fraction and the patient’s fractionation scheme. 
Because prescribed dose is not a mechanical variable, it was not included in the log file for a 
treatment. Instead, the prescribed dose delivered by each beam and the fractionation scheme was 
retrieved from MOSAIQ (Elekta AB, Stockholm, Sweden), software used to track patient 
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information and treatment records. The total workload for each machine was obtained by tallying  
the dose delivered to all patients over the 4 month period. Filtering the master spreadsheet per 
month and per machine, the monthly workload per machine was tallied. Then the daily workload 
per machine can be found based on the number of treatment days in each month. From this, the 
average daily workload was calculated, as well as an average weekly (assumed 5-day work week) 
value for each machine (Table 2.5) to be used in shielding calculations.   
BR2 had the highest workload for VMAT deliveries, nearly a factor of 2 higher than BR1, 
but similar to both CV1 and CV2. The primary reason for this higher workload is that all three 
machines can deliver stereotactic body radiotherapy (SBRT). SBRT treatments deliver large doses 
per fraction in a hypofractionated regimen (Benedict et al., 2010); an order of magnitude more 
radiation is delivered per fraction, but still with only a few arcs. SBRT treatments on BR2, CV1, 
and CV2 result in substantially higher workload, but without a correspondingly larger number of 
delivered arcs compared to the other linacs.  
Table 2.5. Average weekly VMAT workload for each linac for all treatment sites 




















BR1 16673.8 18709.9 19857.4 13621.3 685.0 
BR2 18112.8 11966.6 12536.1 18896.3 944.7 
CV1 16120.4 18714.3 19650.0 14019.4 856.3 
CV2 15578.7 18732.9 19569.8 11039.4 811.5 
GON 15759.3 14999.4 1950.3 13849.3 582.0 
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Due to VMAT’s use of modulated fields to achieve conformality, just like IMRT, shielding 
calculations require a modulation factor to account for the extra radiation produced by the linac 
compared to the radiation delivered to the target. Modulation factor was defined by Report 151 as 
the leakage factor and is calculated with Eq. 4 and Eq. 5 and associated text in Chapter 1. The 
average dose per arc was calculated from the average workload and the average number of arcs 
delivered. The average beam output (MU) per arc was determined from the log file data. The 
average MU for a VMAT delivery was then calculated using Eq. 4. All MBPCC linacs are tuned 
at installation to have an output factor (𝑀𝑈𝑐𝑜𝑛𝑣) of 0.8 cGy/MU for an open field at 6 MV, 
allowing calculation of the modulation factor C using Eq. 5.  Table 2.6 lists the mean dose per arc, 
the mean MU per arc, and the resulting mean modulation factor, as well as the median, IQR, min, 
and max values.  
In previous literature, a VMAT modulation factor of 4.6 ±1.6 was reported (Saleh et al., 2017). 
This reported factor fell within the IQR of this study’s data. Report 151 noted that IMRT 
modulation factors typically fall in the range of 2-10 range (NCRP, 2005), which encompassed the 
mean value of 3.32 found for VMAT in this work.  
Table 2.6. Average modulation factor for VMAT treatments across all five linacs. Figure 




















3.32 3.45 [2.60, 4.28] 0.26 6.82 
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2.4. Summary  
The goal of having well-characterized clinical metrics for the MBPCC facilities and linacs was 
to provide qualified experts with the ability to relate the metrics and results of this project to the 
particular circumstances of their facilities. All data reported in this chapter, for both individual 
treatment sites and individual linacs, is presented in Table 2.7. The total workload is based on the 
classification of each machine’s workload presented in Table 2.5 by treatment site; it is a direct 
summation, not an average value. All average values for daily cases and weekly workloads 
represent the median of the data set, unless otherwise indicated.  
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Table 2.7. Summary of metrics per linac and treatment site. All entries are median values.    












Totals Typical arcs 












86.9 120.8 108.6 102.9 73.8 -- 491.9 
Weekly work- 
load [Gy] 









390.8 539.0 488.5 463.0 332.0 -- 2213.3 
Weekly work- 
load [Gy] 












535.6 738.6 669.5 634.5 455.0 -- 3033.1 
Weekly work- 
load [Gy] 










564.5 778.5 705.7 668.7 479.6 -- 3394.8 
Weekly work- 
load [Gy] 















Total Typical arcs 










839.5 1157.8 1049.5 994.5 713.3 -- 501.1 
Weekly work- 
load [Gy] 










28.9 39.9 36.2 34.3 24.6 -- 4789.6 
Weekly work- 
load [Gy] 








101.3 139.7 126.7 120.0 86.1 -- -- 
Weekly work- 
load [Gy] 










173.7 239.5 217.1 205.8 147.6 --  
Weekly work- 
load [Gy] 





Daily beams 21.5 63.5 36.1 31.9 26.1 308 200 
Workload [Gy] 2,722.9 5,294.7 5,294.7 2,420.4 1,966.4 -- 15,127.4 
Weekly work- 
load [Gy] 
685.0 944.7 856.3 811.5 582.0 -- 3,579.5 
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Chapter 3. VMAT use factors 
This chapter presents methods and results for extracting use factors from the VMAT log files; 
the use factors were quantified and compared over several angular binning intervals. These 
intervals included the 45° and 90° intervals used in Report 151 as well as smaller intervals of 15° 
and 30°. Use factors were examined both as composite values combining all treatment sites and as 
treatment site-specific values. Results were compared to the recommended use factors from Report 
151 and to the assumption of uniform gantry rotation. Chapter 4 provides sample shielding 
calculations that compare the impact of the various use factor results.  
3.1. Methods 
NCRP Report 151 defines the use factor as “the fraction of the weekly workload for which the 
gantry or beam is oriented in [a specified] angular interval centered about [a specified] angle” 
(NCRP, 2005). To determine a use factor, one first specifies the desired range of gantry positions, 
typically as an angular interval centered at a particular position; one then sums the workloads 
delivered at each gantry position within the range, and normalizes to the total workload. Report 
151 notes that the characteristics of a treatment technique, such as total body irradiation and IMRT, 
can significantly impact the use factors, and admonishes qualified experts to assess this as part of 
shielding design. VMAT-specific use factors were extracted from the data in each “.ebin” log file. 
Each entry for a control point recorded the gantry position; therefore, each control point was easily 
assigned to a use factor interval. The total number of control points over which the beam delivers 
radiation was used to normalize the number of control points in each interval. The MBPCC linacs 
were configured to report gantry positions over the range of -180° to +180°, with the 0º position 
referring to the gantry pointing downwards (radiation beam directed towards the floor); a positive 
change in angle represented a clockwise gantry rotation, as one faces the gantry across isocenter. 
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In contrast, Report 151 defines use factors over the range of 0° to 360º. Therefore, each gantry 
position G reported in the VMAT log files was transformed as (𝐺 + 360) 𝑚𝑜𝑑𝑢𝑙𝑜 360, to match 
the convention of Report 151.  A Python script was used to classify all control points into the 
interval ranges of the desired binning scheme. Four binning schemes were assessed: 90º, 45º, 30º, 
and 15º ranges with evenly spaced bins, with the first bin centered at G=0º (i.e. the gantry pointing 
down). Once the gantry position data was classified into the bins, a frequency analysis (i.e., 
normalization to the total number of control points) was done for each bin to obtain the use factor. 
The next section presents the VMAT use factors for the four binning schemes, followed by a 
section comparing these results to the recommended use factors at 90° and 45° intervals of Report 
151. The final section discusses variations in the VMAT use factors between treatment sites.  
3.2. VMAT use factors vs. binning scheme 
Figure 3.1 compares the VMAT use factors for the four binning schemes: 90º, 45º, 30º, and 
15°. These use factors are composite values for all linacs and all treatment sites. In these plots, the 
labels are placed at the corresponding position of the gantry head, e.g., 0º represents the gantry 
head located above the patient and pointing towards the floor while 180° is the gantry head at the 
floor directed up toward the ceiling. Therefore, the wedge located under the 0° label reports the 
use factor for the section of floor below isocenter when the gantry is positioned at 0°. In each 
binning scheme, the VMAT use factor for the interval centered at 180º (beam pointed towards the 
ceiling) was consistently the smallest; to avoid mechanical collision and allow clearance around 
the treatment couch, VMAT plans rarely pass through the 180° gantry position. Similarly, the use 
factor at 0° was consistently larger than the rest. VMAT arcs are typically larger than 180° in span, 




Figure 3.1. VMAT use factors for all treatment sites and all linacs, for the four binning 
schemes: (a) 90°, (b) 45°, (c) 30°, and (d) 15° intervals. The first interval is always 
centered on 0°; this wedge represents the use factor for the floor directly beneath 
isocenter. 
Table 3.1 reports numerical values for the use factors shown in Figure 3.1. The reported 
uncertainties were calculated by averaging the use factors determined for each month of log files. 
These uncertainties were only intended to qualitatively gauge the variability over time of the use 
factors. Appendix B.2 provides mean, median and IQR results and corresponding box plots, as an 
alternative representation to the radar plots of Figure 3.1 and Table 3.1.  
The coarse 90º interval use factors averaged out much of the small variations that were visible 
at the finer binning schemes, especially the 15° interval. The use factors appear to scale between 













































































































in a larger barrier transmission and correspondingly thinner barrier than a coarser scheme. 
However, the finer binning schemes, especially the 15° interval, would likely be the most 
susceptible to variations in use factors due to changes in utilization (overall number of VMAT 
treatments or numbers of deliveries to specific treatment sites). While potentially yielding a short-
term savings in materials and cost, using too fine of a binning scheme could result in inadequate 
barriers. A viable option would be to use the 45º or 30º interval use factors for wall and floor 
calculations to minimize materials, space, and cost; the 30° or even 15° interval use factors would 
be useful for designing a tapered ceiling barrier. These issues are discussed further with the sample 
shielding calculations in Chapter 4. 
3.3. VMAT use factors compared to Report 151 
The 90º and 45º interval binning schemes for use factors allow specific comparison to the 
recommended 90° (conventional) and 45° (IMRT) use factors in Report 151. Figure 3.2, Figure 
3.3, and Table 3.2 provide this comparison. The uncertainties listed in Table 3.2 again represent 
the standard deviation of monthly variations. Overall, the 90º interval VMAT use factors were 
similar to Report 151’s 90º interval use factors, since for conventional treatments each of the four 
directions are about equally weighted. 
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Table 3.1. Summary of the VMAT use factors derived for binning schemes with intervals of 90º, 45º, 30º, and 15°. 
90º interval 45º interval 30º interval 15º interval 
0º 0.271 ± 0.034 0º 0.141 ± 0.018 0º 0.096 ± 0.004 0º 0.050 ± 0.002 
90º 0.248 ± 0.019 45º 0.127 ± 0.010 30º 0.087 ± 0.004 15º 0.048 ± 0.002 
180º 0.240 ± 0.021 90º 0.124 ± 0.011 60º 0.083 ± 0.003 30º 0.045 ± 0.002 
270º 0.242 ± 0.025 135º 0.124 ± 0.015 90º 0.084 ± 0.003 45º 0.044 ± 0.001 
  180º 0.117 ± 0.010 120º 0.084 ± 0.003 60º 0.042 ± 0.001 
  225º 0.121 ± 0.014 150º 0.083 ± 0.004 75º 0.042 ± 0.001 
  270º 0.121 ± 0.014 180º 0.078 ± 0.003 90º 0.043 ± 0.002 
  315º 0.125 ± 0.013 210º 0.082 ± 0.003 105º 0.043 ± 0.001 
    240º 0.081 ± 0.003 120º 0.043 ± 0.002 
    270º 0.082 ± 0.004 135º 0.042 ± 0.002 
    300º 0.081 ± 0.003 150º 0.043 ± 0.002 
    330º 0.088 ± 0.005 165º 0.043 ± 0.002 
      180º 0.035 ± 0.001 
      195º 0.043 ± 0.002 
      210º 0.041 ± 0.002 
      225º 0.041 ± 0.002 
      240º 0.041 ± 0.002 
      255º 0.041 ± 0.002 
      270º 0.042 ± 0.002 
      285º 0.040± 0.002 
      300º 0.040± 0.001 
      315º 0.041± 0.002 
      330º 0.044± 0.003 
      345º 0.046± 0.002 
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Table 3.2. Comparison of VMAT use factors to recommended Report 151 use factors for 
90º and 45° binning intervals.  




0º 0.271 ±0.007 0.310 
90º 0.248 ±0.019 0.213 
180º 0.240 ±0.005 0.263 
270º 0.242 ±0.023 0.213 
45° intervals 
0º 0.141 ±0.006 0.256 
45º 0.127  ±0.011 0.058 
90º 0.124 ±0.010 0.159 
135º 0.124 ±0.009 0.04 
180º 0.117 ±0.003 0.23 
225º 0.121 ±0.012 0.04 
270º 0.121 ±0.013 0.159 
315º 0.125 ±0.011 0.058 
 
More substantial differences are apparent when comparing the use factors at the 45º binning 
intervals. Not surprisingly because of the arc delivery style, the VMAT use factors are closer to 
uniformly distributed; the Report 151 use factors are noticeably smaller in the diagonal directions, 
likely due to a predilection of IMRT treatment planners to favor the four cardinal directions. 
However, as IMRT treatment planning algorithms have evolved, and especially became automated 
for optimization, more complex IMRT treatments with more beams per treatment and routinely 
utilizing more gantry positions have developed, such as illustrated in Figure 1.1 (Saleh et al., 
2017); the 45° interval use factors in Report 151 may themselves be out of date. One should NOT 
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use the Report 151 45° interval use factors when designing shielding for vaults that will be heavily 
used for VMAT. 
 
Figure 3.2. Comparison of the 90°-interval use factors from Report 151 vs. VMAT. The 
error bars represent standard deviation across monthly averages. A fully uniform 
distribution would have a use factor of 0.25 for each interval. 
 
Figure 3.3. Comparison of the 45°-interval use factors from Report 151 vs. VMAT. The 
error bars represent standard deviation across monthly averages. A fully uniform 
distribution would have a use factor of 0.125 for each interval. 
Overall, the VMAT use factors on 45° intervals were relatively uniformly distributed over the 
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continuous arcs. The floor and ceiling showed the highest and lowest use factors, respectively, 
which agreed with the study by Saleh, et.al (Saleh et al., 2017) as shown in Figure 3.4. Saleh’s 
work also showed smaller use factors at 90° and 270°, which were not observed in the current 
work. The discrepancy may be due to differences in the number of VMAT deliveries to a particular 
treatment site (see Section 3.4); insufficient detail about the treatment census in the Saleh work 
limits further discussion of these observed differences.  
 
Figure 3.4. Comparison of VMAT use factor distribution with an angle interval of 30º. The 
rose plot (left) shows the use factors results from previous literature (Source: Saleh, 
et.al, 2017) compared to the radar plot (right) of this study.  
3.4. Use factors by treatment site 
Based on the comparison in the preceding section between the Report 151 45° interval use 
factors and the VMAT 45° interval use factors of this work, one might be tempted to say that the 
VMAT use factors simply represent a uniform distribution of gantry positions. While the results 
do indicate a relatively uniform distribution, one must keep in mind that those results are a 
composite of VMAT deliveries to various treatment sites, each with particular treatment goals and 





























section. Careful consideration must be made by the qualified expert to decide whether the use of 
site-specific vs. generalized use factors are warranted. Report 151 notes:  
“Clearly, when viewed in 90 degree bins these data [use factors] agree with the expected 
traditional “four field” approach to treatment. However, upon closer inspection, some of the 
features that may be unique to a facility begin to appear. For example, a large fraction of 
tangential breast fields would significantly affect the use factor for gantry angles toward the 
wall-floor and wall-ceiling interfaces. It is very important that these be considered, especially 
if any tapering of the barrier thickness is used to account for the beam obliquity.”  
 
Studies previous to this work also indicated the need to consider use factors based on the 
treatment site (Reis et al., 2019). Figure 3.5 shows radar plots of the results of this work’s analysis 
of the use factors based on individual treatment sites. Figure 3.6 shows the same data as 
overlapping line graphs to facilitate comparison. 
Most of the treatment sites followed a relatively uniform distribution of use factors; the two 
exceptions are chest and lung as evident in Figure 3.6. The chest use factors show strong 
asymmetry in the anterior-posterior directions. Anatomically, for treatments of the chest, beams 
are positioned to avoid posterior incidence (i.e the back of the patient) with the patient treated in a 
supine position; the location of the treated volume is usually anterior with respect to the patient, 
such as chest wall and breast. Together these factors strongly bias the chest use factors to arcs that 
move around the anterior of the patient. For the lung, substantial asymmetry is apparent in the left-
right directions. This is because lung treatment plans try to spare the contralateral lung as much as 
possible, so the deliveries are relatively one-sided. (It also appears that the treatment planners may 
routinely reverse the orientation of right- vs. left-lung patients on the treatment table, rather than 
reversing which side of the gantry is used to deliver the arcs.) 
Figure 3.7 compares the composite use factors to the chest-specific use factors, for 45° 
intervals. The deviation of chest use factors from the composite use factors is quite noticeable, 
with the composite values underestimating the chest values for some ranges of gantry motion and 
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overestimating for the rest. In a linac vault that delivers treatments to a mix of sites, the composite 
values would be appropriate to use; but if a vault were to be used heavily (or exclusively) for chest 
treatments, the qualified expert would be wise to use the appropriate site-specific use factors. One 
can make a similar argument for the lung use factors. This issue is addressed further in the sample 
calculations in Chapter 4. 
In summary, one sees that VMAT use factors generally follow a trend of relatively uniform 
rotation, if the linac delivers radiation to a variety of treatment sites. With reasonable conservative 
margins on shielding calculations, both the VMAT use factors presented here vs. use factors based 
on assumed uniform rotation should yield satisfactory vault designs. However, one should not use 
the 45° interval use factors from Report 151 when designing a VMAT vault. Likewise, if a 
particular treatment site will dominate the VMAT deliveries in a vault, the qualified expert should 
consider using treatment site-specific use factors. Sample calculations to illustrate these 







Figure 3.5. VMAT use factors for 45º interval for each treatment site: (a) abdomen, (b) 









































































































































































Figure 3.6. VMAT use factors at 45º intervals for each treatment site. This is the same data 
as shown in the radar plots of Figure 3.6, but shown as overlays for easier 
comparison. 
 
Figure 3.7. VMAT use factors at 45º intervals for the chest treatment side vs. the composite 
of all treatment sites. The composite use factors underestimathe chest use factors 
around the 0° gantry position. 
  
0º 45º 90º 135º 180º 225º 270º 315º
Abdominal 0.134 0.129 0.132 0.130 0.120 0.116 0.116 0.124
Chest 0.183 0.150 0.126 0.097 0.090 0.098 0.104 0.154
H&N 0.145 0.122 0.110 0.118 0.121 0.130 0.123 0.129
Lung 0.160 0.143 0.138 0.148 0.117 0.095 0.092 0.108
Others 0.143 0.126 0.116 0.111 0.112 0.128 0.137 0.128
Pelvis 0.128 0.123 0.130 0.124 0.117 0.125 0.130 0.125
QA 0.135 0.124 0.122 0.122 0.114 0.129 0.123 0.130














0º 45º 90º 135º 180º 225º 270º 315º
Total use factor 0.141 0.127 0.124 0.125 0.118 0.121 0.121 0.124
















Chapter 4. Sample calculations 
In this chapter, sample calculations were used to illustrate the impact of VMAT on shielding 
design. A sample vault layout was created, with the types of areas beyond the barriers chosen to 
represent typical design goals and occupancies that might be encountered. The sample vault was 
modeled after the vault that contains the GON linac at Mary Bird Perkins Cancer Center in 
Gonzalez (D. Neck, private communication). Calculations were performed with realistic 
geometries, assuming a VMAT-only utilization of the vault, and with minimal amounts of 
conservative overestimates, to yield fair comparisons. Comparisons were made for the VMAT use 
factors (combining all sites and all linacs) to the Report 151 recommendations, and also to use 
factors derived by assuming uniform gantry rotation. The potential impact of treatment site-
specific use factors was also assessed.  Barriers were designed with the VMAT use factors to just 
meet the design goals; these were then compared to barriers designed with the other choices for 
use factors, with all other variables held constant. In all calculations, the VMAT workload 
determined for the BR2 linac (see Table 2.5) was used, simply because it was the largest workload 
of the five linacs. 
Barrier thickness (t) based on VMAT use factors, Report 151 use factors, or assumed uniform 
use factors was calculated using Equations 1-7. For additional comparison, the dose equivalent 
(Hshielded) beyond the barrier as designed from either the Report 151 use factors or the assumed 
uniform rotation use factors, but using the VMAT use factors (i.e., assuming the VMAT use factors 
are the true amount of radiation incident on the barrier), were calculated. An adequate barrier must 
satisfy:  
 
𝑃 ≥  Hshielded 
𝐻𝑠ℎ𝑖𝑒𝑙𝑑𝑒𝑑 = 𝐻𝑢𝑛𝑠ℎ𝑖𝑒𝑙𝑑𝑒𝑑𝐵𝑏𝑎𝑟𝑟𝑖𝑒𝑟 
(Eq. 8) 
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The primary unshielded dose equivalent (Hunshielded) was derived from Eq. 1 (essentially, replacing 
the design goal P with Hunshielded and rearranging). The transmission factor (Bbarrier) for an existing 
barrier of thickness t is: 





 (Eq. 9) 
All barriers were designed for standard weight concrete, at a beam energy of 6 MV. 
4.1. Sample vault design 
The sample vault is presented in Figure 4.1. The areas adjacent to the barriers were chosen to 
highlight a realistic scenario for shielding design. The design parameters are summarized in Table 
4.1. Overall vault dimensions and isocenter placement were taken from the design drawings of the 
vault that inspired this layout. AutoCAD LT (Autodesk Inc,  USA) was used to determine distances 
from isocenter to the points of protection located 30 cm past the barriers (NCRP, 2005). The 
weekly workload was 960 Gy/week, based on the VMAT workload of the BR2 linac (Table 2.5). 
Table 4.1. Shielding parameters for the areas beyond barriers A, C, F and CE.  







A (wall) Uncontrolled waiting area 1 20 6.15 
C (wall) Controlled hallway 1 100 3.34 
F (floor) Controlled laboratory 1 100 1.67 







Figure 4.1. Sample vault floor plan. (a) Top view, (b) front elevation through isocenter in 
the gantry’s plane of rotation, and (c) side elevation through isocenter. This floor 








4.2. Sample calculations 
4.2.1. Shielding design: VMAT vs. Report 151 
Report 151 presents two sets of recommendations for use factors: use factors for 90º intervals 
called “conventional” and for 45º intervals called “IMRT”. The 90º use factors are centered on 0º, 
90º, 180º, and 270º gantry positions; the 45° use factors follow the same convention but with 
centers at multiples of 45º. Figure 4.2 depicts the centers of the intervals, showing how each 
corresponds to a particular barrier.  
 
Figure 4.2. Front elevation view through isocenter of the sample vault layout. The red lines 
represent the centers of the use factor intervals.  
Table 4.2 summarizes the barrier thicknesses that result from using the 90° use factors for 
VMAT vs. Report 151. Also listed are the Hshielded values that would result if the Report 151-based 
barrier thickness must protect from the amount of radiation dictated by the VMAT use factor.  
Because the VMAT use factors were larger than the Report 151 use factors for the 90° and 270° 
gantry positions, these barriers (wall A and wall C) if designed with recommended Report 151 use 
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factors would provide inadequate protection from the actual amount of VMAT workload. By 
comparison, the floor and ceiling barriers would be adequate. For the walls, small conservative 
assumptions by the qualified expert such as rounding the barrier thickness to the next inch or 
overestimating the workload (e.g, using 1000 Gy/week instead of 960 Gy/week) would be 
sufficient to achieve an adequate barrier when using the recommended 90° use factors from Report 
151.  
Table 4.2. Comparison of barrier thicknesses when using 90º interval use factors for 
VMAT vs. Report 151. Hshielded is the dose equivalent beyond the barrier when 
radiation in the amount dictated by the VMAT use factor is incident on the barrier 
thickness calculated from the Report 151 use factors. 
 
Barrier 












A-90º 0.248 181 0.213 178 20 22.9 
C-270º 0.242 148 0.213 146 100 107.4 
CE-180º 0.240 156 0.263 158 20 16.9 
F-0º 0.271 208 0.310 210 100 95.9 
 
Table 4.3 summarizes the barrier thicknesses that result from using the 45° use factors for 
VMAT vs. Report 151, as well as the Hshielded values that would result if the Report 151-based 
barrier thickness must protect from the amount of radiation dictated by the VMAT use factor. One 
immediately sees that the barrier thicknesses based on Report 151 use factors in the cardinal 
directions were satisfactory, but the oblique directions were not. The more uniform distribution of 
use factors for VMAT means that the Report 151 use factors underestimate the barrier 
requirements in these oblique directions. Cardinal rather than oblique directions typically dictate 
wall thickness, so this should not be a concern for the walls. However, a tapered ceiling based on 
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Report 151 use factors could be inadequate in these oblique directions despite also having longer 
slanted path lengths. The 45° use factors from Report 151 appear to be adequate for wall barriers, 
but should not be used if one implements a tapered ceiling barrier.  
Table 4.3. Comparison of barrier thicknesses when using 45º interval use factors for 
VMAT vs. Report 151. Hshielded is the dose equivalent beyond the barrier when 
radiation in the amount dictated by the VMAT use factor is incident on the barrier 
thickness calculated from the Report 151 use factors. 
 
Barrier 












A-45º 0.127 120 0.058 112 20 44.4 
A-90º 0.124 171 0.159 174 20 15.1 
A-135º 0.124 121 0.040 109 20 59.3 
C-225º 0.121 95 0.040 83 100 280.9 
C-270º 0.121 138 0.159 142 100 71.0 
C-315º 0.125 97 0.058 89 100 201.2 
CE-135º 0.124 99 0.040 87 20 58.3 
CE-180º 0.117 146 0.230 156 20 9.5 
CE-225º 0.121 98 0.040 87 20 57.6 
F-45º 0.127 108 0.058 100 100 214.7 
F-0º 0.141 168 0.256 176 100 52.4 
F-315º 0.125 112 0.058 105 100 202.1 
 
4.2.2. Shielding design: VMAT vs. uniform-rotation use factors 
Because the logfile-based VMAT use factors exhibited a relatively uniform distribution, a 
qualified expert could conceivably choose to approximate the use factors by assuming uniform 
rotation of the gantry. Table 4.4 compares barrier thickness based on VMAT use factors for 45° 
intervals to those based on a constant use factor of 0.125 for each interval from assuming uniform 
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gantry rotation. While some small differences are seen between the VMAT use factors and the 
constant value of 0.125, simple conservative approaches such as rounding barrier thicknesses to 
the next cm should be sufficient to compensate. No barriers were substantially inadequate. 
Therefore, using a constant use factor for 45º intervals appeared to be a safe and adequate approach 
to barrier design.  
Table 4.4. Comparison of barrier thicknesses when using 45º interval use factors for 
VMAT vs. uniform distribution. Hshielded is the dose equivalent beyond the barrier 
when radiation in the amount dictated by the VMAT use factor is incident on the 
barrier thickness calculated from the uniformly distributed use factors. 
 
Barrier 

















A-45º 0.127 120 0.125 120 20 20.1 
A-90º 0.124 171 0.125 171 20 19.8 
A-135º 0.124 121 0.125 121 20 19.8 
C-225º 0.121 95 0.125 95 100 92.1 
C-270º 0.121 138 0.125 138 100 93.9 
C-315º 0.125 96 0.125 96 100 100 
 
A linac vault’s ceiling may need special attention for shielding design, specifically because 
weight restrictions may make it necessary to take advantage of longer oblique pathlengths by the 
beam through parts of the ceiling. The more segments that are included in a tapered ceiling, the 
more savings that occur in weight, so a tapered ceiling barrier was analyzed for use factors on 30º 
angular intervals to allow for barrier tapering. Like Figure 4.2, Figure 4.3 shows a front elevation 
view of the sample vault, in this case with red lines marking the centers of the 30º intervals for use 
factors. The results of the tapered ceiling calculations are shown in Table 4.5 and Figure 4.4. 
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Figure 4.3. Front elevation view through isocenter of the sample vault layout. The red lines 
represent the center of the use factor angle intervals.  
Compared to using the Report 151 IMRT use factor for the 45° interval centered at 180º, Table 
4.5 shows that the VMAT use factor for this interval would save about 6 cm of concrete thickness 
across the width of the ceiling for an untapered barrier.  The VMAT use factor is also better to use 
than an assumed uniform value for an untapered ceiling, although the savings in material is only 1 
cm. Therefore, assuming uniformly distributed use factors for VMAT is adequate if designed an 
untapered ceiling. For a tapered ceiling design, Report 151 use factors yield an unsatisfactory 
barrier in all lateral segments of the ceiling. Report 151 underestimates the shielding requirements, 
resulting in an unsafe tapered barrier. By comparison, the assumption of uniformly use factors 
results in a tapered ceiling almost identical to the ceiling based on VMAT use factors. 
 
47 
Table 4.5. Comparison of barrier thicknesses in the ceiling (CE) when using 30º interval 
use factors for VMAT vs. uniformly distributed and 45º interval use factors from 
Report 151 vs uniformly distributed.  
 
Barrier 













CE-120º 0.083 62.1 0.083 62.1 0.040 56.8 
CE-150º 0.082 118.8 0.083 119 0.040 109.9 
CE-180º 0.077 139.3 0.083 140.4 0.23 155.0 
CE-210º 0.081 118.6 0.083 118.9 0.058 114.4 
CE-240º 0.080 64.5 0.083 64.8 0.058 62.2 
 
 
Figure 4.4. Front elevation floor plan showcasing the design of a tapered ceiling. Each slab 
represents the barrier thickness from the angle intervals in Table 4.5. The green 
lines represent the barrier design resulting from the assumption of Report 151 use 
factors, and the red lines represent the necessary thickness on the barriers to 
successfully shield for VMAT deliveries. NCRP successfully shields for the 
radiation incident at 180º (gantry pointing up) but yields an inadequate thickness 
for the rest of the slabs.  
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4.3. Other considerations for shielding design 
4.3.1. Site specific use factors 
The use factor analysis in Chapter 3 clearly indicated that the chest and lung treatment sites 
deviated the most from exhibiting a relatively uniform distribution of use factors. This section 
illustrates the potential negative impact of not using treatment site-specific use factors in the 
hypothetical situation of a vault that exclusively treats that site. Essentially, the question is whether 
barriers designed with the composite VMAT use factors will be sufficient if all the workload in 
the vault is delivered according to the chest site’s distribution of use factors. Barrier thicknesses 
were calculated using 30º interval VMAT use factors derived solely from chest VMAT log files, 
and compared to the barrier thicknesses calculated from the composite VMAT use factors (Table 
4.6). Hshielded was calculated with the chest deliveries determining the Hunshielded and the barrier’s 
transmission factor determined from the VMAT barrier thickness.  
Per the dose equivalent presented in Table 4.6, using the composite VMAT use factors (or 
similarly, assuming uniform distribution of use factors) to design a treatment vault that delivers 
only to the chest site would yield adequate barriers except for the floor. For this layout, the only 
instances where the floor was adequate were for the most oblique beams incident on that barrier. 
The floor region below isocenter would need additional concrete thickness to meet the design goal.  
While this specific situation of chest deliveries (not commonly done with VMAT) and floor (rarely 
a barrier with anything located below it) is rather contrived, it serves to illustrate that point that 
heavy utilization of a linac for a specific treatment site can impact shielding design, especially if 
the vault was designed for a more generalized case load. As Report 151 cautions, the qualified 
expert should consider the detailed situation and unique characteristics when designing vault 
shielding.  
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Table 4.6. Comparison of barrier thickness using VMAT and chest 30º interval use factors 
for all barriers, where Hshielded represents the dose equivalent beyond the barrier 
















F-0º 0.096 162 0.123 166 100 127.44 
F-30º 0.088 144 0.113 147 100 128.40 
F-60º 0.082 82 0.086 83 100 20.91 
A-90º 0.083 122 0.083 122 20 20.06 
CE-120º 0.083 82 0.075 81 20 18.06 
CE-150º 0.082 104 0.059 100 20 14.45 
CE-180º 0.077 140 0.059 136 20 15.48 
CE-210º 0.081 119 0.064 116 20 15.79 
C-240º 0.080 75 0.067 74 20 16.77 
C-270º 0.081 133 0.067 133 100 83.22 
F-300º 0.080 65 0.082 65 100 101.88 
F-330º 0.087 144 0.122 148 100 140.19 
 
4.3.2. Secondary barriers, doors, and mazes 
During the shielding design of a radiotherapy treatment vault, the qualified expert must design 
secondary barriers for leakage and patient scatter radiation, as well as consider door and maze 
design. The use factor distributions were the principle shielding parameter that was impacted by 
VMAT. Changes in workload affect all barriers, use factor is 1 by definition for secondary barriers, 
and the modulation factor for VMAT was found to be similar to that for IMRT; thus VMAT should 
not have a particular impact on secondary barriers.  
With respect to door and maze design, Report 151 defines the dose equivalent at the maze 
entrance as a combined product of the secondary radiation due to primary radiation scattered from 
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the patient and walls, leakage radiation scattered from walls, and leakage radiation transmitted 
through the inner maze wall. As with secondary barriers, the amount of secondary radiation 
reaching the door is not impacted by VMAT use factors. In fact, door and maze design typically 
makes the assumption that gantry rotation is uniform (NCRP, 2005), so that the qualified expert 
can scale the contributions of the worst-case wall to account for other barriers’ contributions. The 
relatively uniform distribution of VMAT use factors means that VMAT deliveries easily meet this 
assumption of uniform gantry rotation. 
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Chapter 5. Discussion and conclusion 
5.1. Discussion 
This work analyzed daily log files over a 4-month period for five Elekta linear accelerators at 
several facilities of the Mary Bird Perkins Cancer Center system. The analysis determined VMAT-
specific shielding characteristics from mechanical state data recorded as the linacs delivered 
radiotherapy treatments. The log file data was characterized in terms of treatment-related metrics, 
such as parameters of the treatment arcs, prescribed dose, and treatment site. This data 
characterization can be used by qualified experts to assess the applicability of the results and 
recommendations of this work relative to their own facilities.  
During the 4-month period, VMAT deliveries occurred on all five linacs. Several of the linacs 
had roughly equal amounts of VMAT vs. other types of deliveries, measured by machine MUs. 
Only one linac had VMAT treatments as the substantial majority of its deliveries. The weekly 
workloads derived from the log files for the linacs generally agreed with independent clinic 
records. With the expectation that four months of data for five linacs provided a representative 
snapshot of utilization, the supposition that a linac would be used exclusively for VMAT deliveries 
seems unlikely – certainly not for a small general-purpose facility with only one or two linacs.  
Conceivably at a large institution with many linacs, dedicating a linac to only VMAT treatments 
could be plausible. 
The treatment site metric indicated that the sites treated most frequently with VMAT were 
pelvis, lung, and head & neck. While VMAT was utilized to some extent for all treatment sites, 
VMAT was the dominant choice of treatment method for each of these three sites. VMAT was 
used almost exclusively for treatment of the pelvis (median of 58 VMAT arcs out of 61 beams 
delivered, or 95%) and head and neck (median of 37 VMAT arcs out of 41 beams delivered, or 
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90%).  This indicated that VMAT treatments on a particular linac could indeed be limited to one 
or a few sites; thus treatment-site specific VMAT utilization should be assessed by qualified 
experts for shielding design.  
In prior literature, a VMAT modulation factor of 4.6 ±1.6 was reported (Saleh et al., 2017). 
This modulation factor fell within the IQR of this study’s data, which had a mean of 3.3 in this 
work. Report 151 noted that IMRT modulation factors typically fall in the range of 2-10 (NCRP, 
2005). Modulation factor primarily impacts leakage barrier requirements, so VMAT is not 
expected to alter the design of secondary barriers in terms of leakage, compared to IMRT. 
Similarly, IMRT and VMAT deliver radiation to comparably-sized conformal treatment volumes, 
so the scattered radiation aspects will also be similar.   
Composited over all accelerators and treatment sites, the use factors were computed for binning 
intervals of 90º, 45º, 30º, and 15º. The use factors were relatively uniformly distributed over the 
full circle of gantry motion, with deviations from uniform being the most noticeable at the smaller 
binning intervals and for the 0° (beam directed at floor) and 180° (beam directed at ceiling) gantry 
positions. Not surprisingly, the arc delivery style spread the radiation delivery relatively evenly.  
In the case of the beam directed at the ceiling, the discrepancy became more noticeable at smaller 
binning intervals due to the gantry never being truly at 180º to avoid mechanical collisions with 
the floor and treatment couch. Compared to Report 151, the VMAT use factors were smaller at 0º 
and 180º, but larger at 90º and 270º gantry positions. In retrospect this is not surprising: even 
though lateral beams may not be preferable due to longer pathlengths through normal tissue, they 
are used more frequently in VMAT to achieve conformality while minimizing dose to normal 
tissues (less dose, but delivered over a large volume with broad arcs). The sample calculations 
showed that using VMAT-specific use factors or even the simplified assumption of uniform gantry 
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rotation (a constant use factor at each interval) was consistently more likely to result in a safe 
barrier compared to the Report 151 use factors, especially for the 45° intervals. Qualified experts 
should not use the Report 151 use factors when designing shielding for VMAT vaults. 
The use factors per treatment site were also relatively uniformly distributed, except for lung 
and chest sites. The observed asymmetries in distribution were likely due to the site’s proximity 
to organs at risk in the thorax, especially contralateral lung. The sample calculations showed that 
for a vault dedicated to chest deliveries, areas in the floor could be inadequately shielded. Although 
the chest itself was not specifically interesting (the site was not prevalent for VMAT and the floor 
is rarely a concern due to vaults being routinely placed on the lowermost floor of a facility), this 
example emphasized that the characteristics of particular treatment sites may strongly impact the 
adequacy of a shielding design.   
The sample calculations for vault shielding designs showed that the Report 151 use factors 
may underestimate barrier requirements for a vault used predominantly for VMAT. While the 
inclusion of substantial conservative margins on calculations should allow Report 151-based 
barriers to be adequately safe, further investigation would be needed to quantify the level of margin 
needed. Such designs would overshield the vault compared to the VMAT use factors or the 
assumption of uniform gantry rotation, potentially wasting money and material. The inadequacy 
of Report 151 use factors would be most likely to impact a tapered ceiling barrier design rather 
than walls or other barriers. Using the VMAT use factors or use factors derived from an assumption 
of uniform rotation should provide the best savings in materials while also ensuring a safe design. 
5.1.1. Broader applicability of the current work 
The independent analysis of the clinical records indicated good correspondence between the 
workload, use factor, and modulation factor results because a large pool of data was acquired. 
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Regardless, the extent of the generalization of the obtained data is still not understood and out of 
the scope of this project to characterize. This work included a detailed analysis of the weekly 
workload for the Mary Bird Perkins Cancer Center facilities, but this data was limited to a single 
manufacturer and two similar machine models. Regardless, substantial differences compared to 
other linac manufacturers and models, or to operations at other clinics, would seem unlikely; the 
spatial distribution of use factors and the modulation factors should be similar, as they are based 
on the same underlying physics, biology, and treatment goals. Regardless of the clinic, physician 
or dosimetrist, radiation transport and radiobiological effects dictate that treatment deliveries will 
be substantially similar across patients for each case type. The results presented here should be 
generally applicable across accelerator models and vendors; differences between facilities should 
be primarily due to differences in patient census, that is, the numbers of treatments to a particular 
tumor site or sites. Again, qualified experts must assess their particular circumstances to decide 
whether the results of this work should be used to represent their own clinical environment. 
5.2. Conclusions 
The use factors recommended in Report 151 are not guaranteed to provide safe barriers for 
linac vaults used heavily for VMAT, although sufficiently large conservative margins could 
potentially overcome the deficits. When designing the shielding for vaults that will be used 
predominately for VMAT, qualified experts should use VMAT-specific use factors. The VMAT-
specific use factors reported in this work consistently led to primary barrier thicknesses that were 
at least as safe as those calculated from published Report 151 use factors. If VMAT-specific use 
factors are not available, the assumption of uniform gantry rotation (i.e., a constant use factor at 
each interval) is a reasonable alternative. Smaller (i.e., 30° or 45°) intervals for use factors result 
in thinner barriers than do larger (i.e., 90°) intervals, although smaller intervals would presumably 
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be more susceptible to variations in utilization or changes in VMAT delivery methods. Smaller 
intervals are attractive when designing a tapered ceiling barrier in a dedicated VMAT vault, and 
should result in a ceiling barrier that is safe while using less material; the 45° interval use factors 
from Report 151 should not be used to design a tapered ceiling barrier in a dedicated VMAT vault. 
Finally, if a vault will be used exclusively for VMAT, and especially for only one or a few 
treatment sites, the qualified expert should develop and use institution-specific treatment site-
specific use factors or verify that composite VMAT use factors will be satisfactory. 
The log file data for this work was accumulated over a four-month period for five linacs. This 
work has assumed this data to be representative of current practice. To ensure representative data, 
one should continue collecting log files for a long period, combining the additional data with the 
data reported here. For data that is representative of national practice, one should consider 
collecting data from multiple institutions. In addition, all linacs used in this work were Elekta 
Versa and Agility models. Again, to ensure representative data, VMAT-specific data should be 
collected for a wide range of vendors and models. 
This work originally planned to make TLD measurements on barrier surfaces inside the linac 
vaults, to validate the workload and use factors derived from log files. TLD measurements could 
also be used to assess the magnitudes of secondary radiation at the barriers. Access restrictions 
due to the COVID pandemic, coupled to a failure of the TLD reader, prevented the incorporation 
of TLD measurements in this work. These validation measurements should be pursued in the future 







Figure A.1. Boxplot representation of the daily deliveries for (upper) all delivered beams 
and (lower) VMAT arcs only. The box sides represent interquartile range (IQR), 
this range contains 50% of the data points. The line within the IQR is the median, 
with the cross being the mean. The whiskers are the minimum and maximum values 
of the data range, and the outlying data points are the points greater or inferior to 
1.5 times the IQR. 
 
Appendix A. Clinical metrics 
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Figure A.2. Boxplot illustrating the frequency of machine usage for all delivery types, 
where the box sides represent interquartile range (IQR) which contains 50% of the 
data points. The line within the IQR is the median, with the cross marking the mean. 
The whiskers mark the minimum and maximum values of the data range, and the 
outlying data points are the points greater or inferior to 1.5 times the IQR. 
 
Figure A.3. Boxplot illustrating the VMAT modulation factor, where the box sides 
represent interquartile range (IQR) which contains 50% of the data points. The line 
within the IQR is the median, with the cross marking the mean. The whiskers mark 
the minimum and maximum values of the data range, and the outlying data points 
are the points greater or inferior to 1.5 times the IQR. 
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Appendix B. Use factors 
Table B.1. Summary of VMAT use factors derived with intervals of 90°. 
Bin Frequency Use Factor 
0º 592958 0.271 
90º 542831 0.248 
180º 524399 0.240 
270º 529026 0.242 
Table B.2. Summary of the VMAT use factors derived with intervals of 45°. 
Bin Frequency Use Factor 
0º 310328 0.141 
45º 279031 0.127 
90º 272101 0.124 
135º 272614 0.124 
180º 257008 0.117 
225º 264611 0.121 
270º 265216 0.121 
315º 273232 0.125 
Table B.3. Summary of the VMAT use factors derived with intervals of 30°. 
Bin Frequency Use Factor 
0 210645 0.096 
30 192467 0.088 
60 179321 0.082 
90 181765 0.083 
120 181745 0.083 
150 180013 0.082 
180 168072 0.077 
210 176314 0.081 
240 175695 0.080 
270 177502 0.081 
300 175829 0.080 




Table B.4. Summary of the VMAT use factors derived with intervals of 15°. 
Bin Frequency Use Factor 
0 107157 0.049 
15 101863 0.047 
30 95806 0.044 
45 93499 0.043 
60 89012 0.041 
75 89241 0.041 
90 91028 0.042 
105 91056 0.042 
120 91414 0.042 
135 88771 0.041 
150 91768 0.042 
165 91651 0.042 
180 73868 0.034 
195 91088 0.042 
210 88059 0.041 
225 88620 0.041 
240 87386 0.040 
255 88135 0.040 
270 89201 0.041 
285 87287 0.040 
300 87918 0.040 
315 89420 0.041 
330 95253 0.044 
345 100713 0.046 
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Table B.5. Angular mean, median and IQR of the data distribution for 90º angle intervals. 
The data is shown as a boxplot in Figure B.1. 
Bin Mean Median IQR 
0º 0.3 0.3 [338.7, 21.8] 
90º 90.1 90.3 [67.6,112.7] 
180º 179.8 176.1 [135.1, 202.7] 
270º 270.1 270.0 [247.6, 292.6] 
 
Figure B.1. Boxplot illustrating the angle bin data at 90º angular intervals, where the box 
sides represent interquartile range (IQR) which contains 50% of the data points. 
The line within the IQR is the median, with the cross marking the mean. The 
whiskers mark the minimum and maximum values of the data range. 
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Table B.6. Angular mean, median and IQR of the data distribution for 45º angle interval. 
The data is shown as a boxplot in Figure B.2. 
Bin Mean Median IQR 
0º 0.08 0.1 [349.2, 10.9] 
45º 44.6 44.5 [33.3, 55.8] 
90º 90.2 90.2 [79.0, 101.4] 
135º 135.0 135.0 [123.7, 146.4] 
180º 180.0 180.6 [168.3, 191.9] 
225º 225.0 225.0 [213.8, 236.2] 
270º 270.0 269.9 [258.8, 281.2] 
315º 315.5 315.7 [304.2, 326.8] 
 
 
Figure B.2. Boxplot illustrating the angle bin data at 45º angular intervals, where the box 
sides represent interquartile range (IQR) which contains 50% of the data points. 
The line within the IQR is the median, with the cross marking the mean. The 
whiskers mark the minimum and maximum values of the data range. 
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Table B.7. Angular mean, median and IQR of the data distribution in 30º angle intervals. 
The data is shown as a boxplot in Figure B.3. 
Bin Mean Median IQR 
0º 0.12 0.1 [352.8, 7.5] 
30º 29.8 29.7 [22.4, 37.4] 
60º 59.9 59.8 [52.3, 67.4] 
90º 90.1 90.1 [82.6, 97.6] 
120º 120.0 120.0 [112.5, 127.4] 
150º 157.4 150.1 [142.7, 157.4] 
180º 180.0 180.4 [171.8, 188.3] 
210º 210.0 210.1 [202.5, 217.5] 
240º 240.0  240.0 [232.5, 247.5] 
270º 270.0  269.9 [262.6, 277.5] 
300º 300.1  300.2 [292.6, 307.7] 






Figure B.3. Boxplot illustrating the angle bin data at 30º angular intervals, where the box 
sides represent interquartile range (IQR) which contains 50% of the data points. 
The line within the IQR is the median, with the cross marking the mean. The 
whiskers mark the minimum and maximum values of the data range. 
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Table B.8. Angular mean, median and IQR of the data distribution in 30º angle intervals. 
The data is shown as a boxplot in Figure B.4. 
Bin Mean Median IQR 
0º 0.05 0.1 [356.3, 3.8] 
15º 15.0 14.8 [11.2, 18.6] 
30º 29.9 29.8 [26.2, 33.6] 
45º 45.0 45.0 [41.3, 48.7] 
60º 60.0 60.0 [56.2, 63.8] 
75º 75.1 75.2 [71.4, 78.8] 
90º 90.1 90.1 [86.4, 93.8] 
105º 105.0 105.0 [101.3, 108.9] 
120º 120.1 120.0 [116.2, 123.8] 
135º 135.0 135.1 [131.3, 138.7] 
150º 150.0 150.0 [146.3, 153.7] 
165º 165.2 165.3 [161.5, 169.1] 
180º 180.0 180.7 [174.8, 185.2] 
195º 194.9 194.8 [191.1, 198.6] 
210º 210.1 210.1 [206.3, 213.8] 
225º 225.0 225.1 [221.3, 228.8] 
240º 240.0 240.1 [236.3, 243.8] 
255º 255.1 255.1 [251.4, 258.8] 
270º 270.0 270.0 [266.3, 273.7] 
285º 285.0 285.0 [281.4, 288.8] 
300º 300.1 300.1 [296.3, 303.8] 
315º 315.1 315.1 [311.4, 318.8] 
330º 330.1 330.1 [326.3, 333.8] 




Figure B.4. Boxplot illustrating the angle bin data at 15º angular intervals, where the box 
sides represent interquartile range (IQR) which contains 50% of the data points. 
The line within the IQR is the median, with the cross marking the mean. The 










Table B.9. Summary of the abdomen VMAT use factors for angle intervals of 90º, 45º, 30º, 15º. 
90º angle interval 45º angle interval 30º angle interval 15º angle interval 
0º 0.265 0º 0.134 0º 0.090 0º 0.044 
90º 0.260 45º 0.129 30º 0.087 15º 0.045 
180º 0.242 90º 0.132 60º 0.085 30º 0.044 
270º 0.232 135º 0.130 90º 0.089 45º 0.043 
  180º 0.120 120º 0.086 60º 0.043 
  225º 0.116 150º 0.087 75º 0.043 
  270º 0.116 180º 0.078 90º 0.044 
  315º 0.124 210º 0.077 105º 0.044 
    240º 0.077 120º 0.043 
    270º 0.078 135º 0.044 
    300º 0.077 150º 0.042 
    330º 0.088 165º 0.044 
      180º 0.037 
      195º 0.039 
      210º 0.039 
      225º 0.039 
      240º 0.039 
      255º 0.039 
      270º 0.038 
      285º 0.039 
      300º 0.038 
      315º 0.044 
      330º 0.042 
      345º 0.045 
 
67 
Table B.10. Summary of the chest VMAT use factors for angle intervals of 90º, 45º, 30º, 15º. 
90º angle interval 
45º angle interval 30º angle interval 15º angle interval 
0º 0.357 0º 0.183 0º 0.123 0º 0.064 
90º 0.244 45º 0.150 30º 0.113 15º 0.060 
180º 0.182 90º 0.126 60º 0.086 30º 0.058 
270º 0.217 135º 0.097 90º 0.083 45º 0.049 
  180º 0.090 120º 0.075 60º 0.043 
  225º 0.098 150º 0.059 75º 0.040 
  270º 0.104 180º 0.059 90º 0.040 
  315º 0.154 210º 0.064 105º 0.046 
    240º 0.067 120º 0.036 
    270º 0.067 135º 0.031 
    300º 0.082 150º 0.030 
    330º 0.122 165º 0.031 
      180º 0.026 
      195º 0.032 
      210º 0.032 
      225º 0.033 
      240º 0.033 
      255º 0.035 
      270º 0.033 
      285º 0.035 
      300º 0.041 
      315º 0.044 
      330º 0.069 
      345º 0.059 
68 
Table B.11. Summary of the head & neck VMAT use factors for angle intervals of 90º, 45º, 30º, 15º.
90º angle interval 45º angle interval 30º angle interval 15º angle interval 
0º 0.276 0º 0.145 0º 0.100 0º 0.052 
90º 0.226 45º 0.122 30º 0.087 15º 0.047 
180º 0.248 90º 0.110 60º 0.076 30º 0.044 
270º 0.250 135º 0.118 90º 0.073 45º 0.041 
  180º 0.121 120º 0.077 60º 0.038 
  225º 0.130 150º 0.080 75º 0.037 
  270º 0.123 180º 0.079 90º 0.036 
  315º 0.129 210º 0.089 105º 0.037 
    240º 0.084 120º 0.038 
    270º 0.082 135º 0.039 
    300º 0.084 150º 0.041 
    330º 0.089 165º 0.041 
      180º 0.033 
      195º 0.047 
      210º 0.044 
      225º 0.044 
      240º 0.042 
      255º 0.041 
      270º 0.041 
      285º 0.041 
      300º 0.042 
      315º 0.043 
      330º 0.044 
      345º 0.047 
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Table B.12. Summary of the lung VMAT use factors for angle intervals of 90º, 45º, 30º, 15º.
90º angle interval 45º angle interval 30º angle interval 15º angle interval 
0º 0.290 0º 0.160 0º 0.110 0º 0.055 
90º 0.284 45º 0.143 30º 0.096 15º 0.052 
180º 0.238 90º 0.138 60º 0.095 30º 0.047 
270º 0.188 135º 0.148 90º 0.092 45º 0.049 
  180º 0.117 120º 0.097 60º 0.047 
  225º 0.095 150º 0.098 75º 0.046 
  270º 0.092 180º 0.077 90º 0.046 
  315º 0.108 210º 0.063 105º 0.046 
    240º 0.062 120º 0.050 
    270º 0.062 135º 0.047 
    300º 0.064 150º 0.051 
    330º 0.084 165º 0.050 
      180º 0.033 
      195º 0.034 
      210º 0.031 
      225º 0.032 
      240º 0.031 
      255º 0.030 
      270º 0.031 
      285º 0.031 
      300º 0.033 
      315º 0.032 
      330º 0.043 
      345º 0.052 
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Table B.13. Summary of the others VMAT use factors for angle intervals of 90º, 45º, 30º, 15º.
90º angle interval 45º angle interval 30º angle interval 15º angle interval 
0º 0.280 0º 0.143 0º 0.095 0º 0.049 
90º 0.228 45º 0.126 30º 0.094 15º 0.048 
180º 0.229 90º 0.116 60º 0.074 30º 0.049 
270º 0.264 135º 0.111 90º 0.079 45º 0.041 
  180º 0.112 120º 0.075 60º 0.037 
  225º 0.128 150º 0.072 75º 0.038 
  270º 0.137 180º 0.074 90º 0.040 
  315º 0.128 210º 0.084 105º 0.038 
    240º 0.088 120º 0.038 
    270º 0.093 135º 0.036 
    300º 0.083 150º 0.036 
    330º 0.090 165º 0.035 
      180º 0.033 
      195º 0.044 
      210º 0.042 
      225º 0.042 
      240º 0.043 
      255º 0.047 
      270º 0.046 
      285º 0.044 
      300º 0.041 
      315º 0.042 
      330º 0.045 
      345º 0.046 
71 
Table B.14. Summary of the pelvis VMAT use factors for angle intervals of 90º, 45º, 30º, 15º.
90º angle interval 45º angle interval 30º angle interval 15º angle interval 
0º 0.251 0º 0.128 0º 0.087 0º 0.049 
90º 0.254 45º 0.123 30º 0.082 15º 0.044 
180º 0.239 90º 0.130 60º 0.082 30º 0.043 
270º 0.256 135º 0.124 90º 0.088 45º 0.040 
  180º 0.117 120º 0.084 60º 0.041 
  225º 0.125 150º 0.081 75º 0.041 
  270º 0.130 180º 0.076 90º 0.042 
  315º 0.125 210º 0.082 105º 0.044 
    240º 0.085 120º 0.043 
    270º 0.088 135º 0.042 
    300º 0.084 150º 0.040 
    330º 0.083 165º 0.041 
      180º 0.041 
      195º 0.035 
      210º 0.041 
      225º 0.041 
      240º 0.041 
      255º 0.042 
      270º 0.043 
      285º 0.044 
      300º 0.042 
      315º 0.042 
      330º 0.042 
      345º 0.041 
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Table B.15. Summary of the QA VMAT use factors for angle intervals of 90º, 45º, 30º, 15. 
90º angle interval 45º angle interval 30º angle interval 15º angle interval 
0º 0.260 0º 0.135 0º 0.091 0º 0.046 
90º 0.245 45º 0.124 30º 0.083 15º 0.045 
180º 0.242 90º 0.122 60º 0.083 30º 0.041 
270º 0.253 135º 0.122 90º 0.082 45º 0.041 
  180º 0.114 120º 0.080 60º 0.041 
  225º 0.129 150º 0.083 75º 0.040 
  270º 0.123 180º 0.072 90º 0.042 
  315º 0.130 210º 0.087 105º 0.041 
    240º 0.083 120º 0.040 
    270º 0.084 135º 0.040 
    300º 0.086 150º 0.042 
    330º 0.086 165º 0.040 
      180º 0.030 
      195º 0.045 
      210º 0.044 
      225º 0.043 
      240º 0.042 
      255º 0.040 
      270º 0.041 
      285º 0.043 
      300º 0.044 
      315º 0.044 
      330º 0.042 
      345º 0.044 
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Table B.16. Summary of the spine VMAT use factors for angle intervals of 90º, 45º, 30º, 15º. 
90º angle interval 45º angle interval 30º angle interval 15º angle interval 
0º 0.255 0º 0.131 0º 0.090 0º 0.048 
90º 0.266 45º 0.134 30º 0.092 15º 0.048 
180º 0.247 90º 0.143 60º 0.087 30º 0.046 
270º 0.231 135º 0.126 90º 0.097 45º 0.043 
  180º 0.120 120º 0.082 60º 0.043 
  225º 0.111 150º 0.087 75º 0.045 
  270º 0.120 180º 0.085 90º 0.050 
  315º 0.115 210º 0.076 105º 0.046 
    240º 0.074 120º 0.041 
    270º 0.081 135º 0.039 
    300º 0.076 150º 0.044 
    330º 0.074 165º 0.048 
      180º 0.038 
      195º 0.040 
      210º 0.037 
      225º 0.038 
      240º 0.036 
      255º 0.041 
      270º 0.040 
      285º 0.039 
      300º 0.039 
      315º 0.036 
      330º 0.037 
      345º 0.037 
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Figure B.5. VMAT use factors at 90º intervals for each treatment site. This is the same data 
as shown in the radar plots of Figure 3.6, but shown as overlays for easier 
comparison. 
 
Figure B.6. VMAT use factors at 45º intervals for each treatment site. This is the same data 
as shown in the radar plots of Figure 3.6, but shown as overlays for easier 
comparison. 
0º 90º 180º 270º
Abdominal 0.265 0.260 0.242 0.232
Chest 0.357 0.244 0.182 0.217
Head&Neck 0.276 0.226 0.248 0.250
Lung 0.290 0.284 0.238 0.188
Others 0.280 0.228 0.229 0.264
Pelvis 0.251 0.254 0.239 0.256
QA 0.260 0.245 0.242 0.253














0º 45º 90º 135º 180º 225º 270º 315º
Abdominal 0.134 0.129 0.132 0.130 0.120 0.116 0.116 0.124
Chest 0.183 0.150 0.126 0.097 0.090 0.098 0.104 0.154
H&N 0.145 0.122 0.110 0.118 0.121 0.130 0.123 0.129
Lung 0.160 0.143 0.138 0.148 0.117 0.095 0.092 0.108
Others 0.143 0.126 0.116 0.111 0.112 0.128 0.137 0.128
Pelvis 0.128 0.123 0.130 0.124 0.117 0.125 0.130 0.125
QA 0.135 0.124 0.122 0.122 0.114 0.129 0.123 0.130
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